APVO Stock Forecast: Aptevo Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.40
−2.39% on the day

The median 12-month analyst price target for Aptevo Therapeutics, Inc. is $21. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 29 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$1.4M
Ticker Nerd rank
29/ 100
Median analyst target
$21
Analysts covering
1
Revenue$0.0
Operating income−$6.4M
Net income−$6.4M
Free cash flow−$5.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−32.0%
1M
−75.0%
YTD
−95.7%
1Y
−97.9%
From 52W high
−98.4%
From 52W low
0.0%
$0
$25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Aptevo Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
29/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
84
Growth
68
Volatility
61
Revisions
35
Issuance
21
Quality
20
Value
12
Momentum
2

Accruals (84): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

APVO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on APVO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25Jan 26Apr 26Jul 26Oct 26APVOHigh $21Median $21Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$20
Low
$21
Median
$21
High
Recent analyst actionsNewest first

Of the 9 most recent actions, 1 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
23 Sept 2024Roth MKMMaintainsBuy$15 → $8.00
13 May 2022Piper SandlerMaintainsOverweight$69 → $20
28 May 2021Roth CapitalMaintainsBuy$64 → $50
25 Nov 2020PiperJaffrayInitiatesOverweight—
25 Nov 2020Roth CapitalInitiatesBuy—
11 Nov 2020Piper SandlerMaintainsOverweight$32 → $69
11 Apr 2018Roth CapitalInitiatesBuy—
9 Sept 2016Piper SandlerInitiatesOverweight—
9 Sept 2016PiperJaffrayInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for APVO.

Market Radar

This page is one stock. Monday covers all of them.

APVO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

APVO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Aptevo Therapeutics, Inc. returned −97.9% against +6.9% for the S&P 500, dividends included.

APVO vs S&P 500, last 12 monthsTotal return, rebased to 100
050100Jan 26Apr 26Jul 26Oct 26APVOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

APVO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 98% of US stocks

Price / sales
—
Price / book
0.0×

Cheaper than 98% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−420.3%

Higher than 3% of US stocks

Return on assets
−111.5%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aptevo Therapeutics, Inc. has a market value of $1.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$26.4M.

  • Free cash flow in the twelve months to 30 June 2026: −$25.3M.

  • Shares outstanding: 1.2M.

  • Trailing P/E: 0.0×.

  • Aptevo Therapeutics, Inc. employs 33 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

APVO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
APVOAptevo Therapeutics, Inc.$1.4M29
BRTXBioRestorative Therapies, Inc.$1.4M6
CMNDClearmind Medicine, Inc.$1.3M6
ELABPMGC Holdings, Inc.$1.3M3
ARTLArtelo Biosciences, Inc.$1.3M24
ENLVEnlivex Ltd.$1.6M4
JUNSJupiter Neurosciences, Inc.$1.6M14

Take a look at APVO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Aptevo Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about APVO

What is the APVO stock price forecast for 2026-2027?

The median 12-month analyst price target for Aptevo Therapeutics, Inc. is $21, with estimates ranging from $20 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is APVO stock a buy right now?

Of the 1 analyst covering Aptevo Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aptevo Therapeutics, Inc. 29 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank APVO?

As at 21 Nov 2026, Aptevo Therapeutics, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (84 of 100).

Will APVO stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $21, and Ticker Nerd's factor model ranks Aptevo Therapeutics, Inc. 29 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the APVO stock forecast for 2030?

No analyst covering Aptevo Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APVO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $21 over the next 12 months.

How has APVO stock performed over the past year?

Aptevo Therapeutics, Inc. returned -97.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aptevo Therapeutics, Inc. do?

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapy candidates for cancer. The company uses its proprietary ADAPTIR and ADAPTIR-FLEX platforms to design mono-, bi-, and multi-specific antibody-based therapeutics intended to engage the immune system against tumor cells.

Company

About Aptevo Therapeutics, Inc.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapy candidates for cancer. The company uses its proprietary ADAPTIR and ADAPTIR-FLEX platforms to design mono-, bi-, and multi-specific antibody-based therapeutics intended to engage the immune system against tumor cells. Its current pipeline includes candidates for hematologic malignancies and solid tumors, with programs spanning clinical and preclinical development. Aptevo Therapeutics Inc. operates in the oncology and immuno-oncology segments of the healthcare market, where it contributes to the development of targeted biologic therapies for complex cancers. Headquartered in Seattle, Washington, the company concentrates on research-driven product development and collaboration-based innovation in modern cancer treatment.

CEO Mr. Jeffrey G. Lamothe CA · 33 employees · United States · https://aptevotherapeutics.com